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Abstract 
Background: Artemisinin resistance has been reported in Greater Mekong Sub‑region countries, including Myanmar. 
After discovery of artemisinin resistance marker (K13), molecular surveillance on artemisinin resistance in endemic 
regions have been conducted. As the migrant population represents a high percentage of malaria cases, molecular 
surveillance of artemisinin resistance among migrant workers is of great concern.
Methods: A cross‑sectional survey was conducted in Shwegyin Township, where migrants work in the goldmines. 
Blood samples were collected from uncomplicated Plasmodium falciparum‑infected migrant workers by active and 
passive cases screening with rapid diagnostic testing (RDT) and microscopy. Amplification and sequence analysis of 
artemisinin resistance molecular markers, such as k13, pfarps10, pffd, pfmdr2, pfmrp1, pfrad5, and pfcnbp, were carried 
out and pfmdr1 copy number analysis was conducted by real‑time PCR.
Results: Among the 100 falciparum‑infected patients, most were male (90%), of working age (20–40 years) with 
median parasite density of 11,166 parasites/µL (range 270–110,472 parasites/µL). Artemisinin resistance molecular 
marker, k13 mutations were detected in (21/100, 21.0%) in which composed of a validated marker, C580Y (9/21, 
42.9%) and candidate markers such as P574L (5/21, 23.8%), P667T (5/21, 23.8%) and M476I (2/21, 9.5%). Underlying 
genetic markers predisposing to become k13 mutants were found as V127M of pfarps10 (41/100, 41.0%), D153Y of 
pffd (64/100, 64.0%), T484I of pfmdr2 (58/100, 58.0%) and F1390I of pfmrp1 (24/100, 24.0%). The pfmdr1 copy number 
analysis revealed six copy numbers (1/100, 1.0%), three (2/100, 2.0%), two (8/100, 8.0%) and only one copy number 
(89/100, 89.0%). Only one sample showed both k13 mutation (P667T) and multiple copy number of pfmdr1.
Conclusions: High mutant rate of artemisinin resistance markers and relatively high pfmdr1 copy number among 
isolates collected from migrant goldmine workers alert the importance of containment measures among this target 
population. Clinical and molecular surveillance of artemisinin resistance among migrants should be scaled up.
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Background
Artemisinin-based combination therapy (ACT) is the most 
effective anti-malarial treatment for falciparum malaria [1]. 
However, artemisinin resistance was reported in clinical 
studies in Cambodia as early as 2006 [2], followed by other 
Southeast Asian counties, including Myanmar, Laos, Thai-
land, and Vietnam [3]. In Myanmar, delayed clearance of 
the parasite after treatment with ACT has been reported 
since 2009 in southern Myanmar [2] and reduced suscep-
tibility of artesunate was observed in 2010 [4]. In Myan-
mar, a multifaceted artemisinin resistance containment 
programme was initiated in 2011 [5] and, according to 
the global plan for artemisinin resistance containment 
(GPARC), artemisinin resistance zones were categorized as 
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Tier I: where there was evidence of artemisinin resistance; 
Tier II: where there was suspected evidence of artemisinin 
resistance; and Tier III: the remaining malaria prevalence 
areas [6]. According to the MARC programme, migrant 
and mobile populations are highly vulnerable and the 
potential spreader of resistant parasites [7].
The worldwide burden of malaria has been decreas-
ing significantly and the number of countries moving to 
malarial elimination is increasing [8]. The World Health 
Organization (WHO) has initiated a strategy for malaria 
elimination in the Greater Mekong Sub-region by 2030 
[9]. Drug resistance is one of the challenges to success-
fully achieving this goal [10]. Surveillance of artemisinin 
resistance along with appropriate action to eliminate 
resistant strains is important in successfully contain-
ment of the resistant parasite. After the discovery of 
artemisinin resistance molecular markers (k13), world-
wide prevalence of these markers was documented [11, 
12]. Other markers, such as pfmrp1 (multidrug resistance 
protein 1 gene), pfcnbp (cyclic nucleotide-binding pro-
tein) and pfrad5 (DNA repair protein RAD5 homologue) 
were also identified as potential drug resistance mark-
ers [13]. A genome-wide association study reported that 
pfarps10 (apicoplast ribosomal protein S10), pffd (ferre-
doxin), pfmdr2 (multidrug resistance protein 2) and pfcrt 
(chloroquine resistance transporter) gene mutations are 
significantly associated with delayed clearance of para-
sites after ACT, indicating the underlying genetic back-
ground for artemisinin resistance [14].
Migrant and mobile populations are a major concern 
for malaria transmission and are a target group for the 
artemisinin containment programme implemented in 
Myanmar, Laos, Cambodia, Thailand, and Vietnam [15, 
16]. Because of the nature of these populations, it is diffi-
cult to conduct regular longitudinal monitoring and sur-
veillance of the occurrence of malaria in these groups. In 
this study, molecular marker analysis was carried out in 
one gold mining area in Myanmar to assess the status and 
distribution of artemisinin resistance.
Methods
Study design and study population
This cross-sectional analysis study was conducted in 
Shwegyin (22°20′0″ N, 95°56′0″ E), one township of the 
Myanmar artemisinin resistance containment (MARC) 
zone (Fig.  1). According to the 2014 census, a popula-
tion of 107,462 was living in 2440.1 sq km. As the Shw-
egyin area is famous for gold mining, migrant and mobile 
populations are working in the deep forest goldmine and 
bearing a high burden of malaria as compared to the 
neighbour township (Fig.  1). Moreover, the majority of 
reported malaria cases come from the migrant popula-
tion in Shwegyin (Fig. 2) [17].
Uncomplicated Plasmodium falciparum-infected 
samples from migrant goldminers or their family mem-
bers were collected from Shwegyin during 2013–2015. 
Active and passive cases detection was carried out for 
sample collection. All malaria suspected cases were ini-
tially screened by rapid diagnostic testing (RDT) fol-
lowed by microscopy examination of peripheral blood 
smear. The patients with parasite count more than 500/
µL were included in the study although all positive cases 
were treated according to the national malaria treatment 
guideline. Whole blood samples were collected in EDTA-
coated tubes for further molecular analysis.
DNA extraction, amplification and sequencing
Parasite DNA was extracted from the whole blood using 
QIAamp DNA Blood Mini Kit (QIAGEN) according to 
manufacturer’s instruction. A nested PCR approach was 
designated to amplify target genes using a specific pair 
of primers (Additional file  1). Amplifications were per-
formed in a reaction mixture that contained 0.25  mM 
of each dNTP, 10  mM Tris–HCl (pH 9.0), 30  mM KCl, 
1.5  mM MgCl2, 1.0 units of Taq polymerase (Bioneer, 
Seoul, Korea), 0.02  µM primers, and 2  µl of genomic 
DNA. For target gene amplifications, initial denatura-
tion at 95 °C for 5 min was followed by 35 cycles of 95 °C 
for 30 s, 58 °C for 1 min (k13, pfarps10, pfmdr2) or 62 °C 
for 1 min (pffd), 72 °C for 1.5 min, and a final extension 
of 72 °C for 10 min. Using 1 µL of the nested-1 product 
as a template, the same conditions were applied for the 
nested-2 PCR except for an annealing temperature of 
60  °C for 1  min (k13, pffd, pfmdr2) or 62  °C for 1  min 
(pfarps10) and 72 °C for 1 min with 30 cycles.
For pfmrp1, pfcnbp and pfrad5 gene amplification, PCR 
was performed with an initial denaturation at 94  °C for 
5 min and 30 cycles at 94 °C for 30 s, 56 °C for 30 s, and 
72  °C for 1 min. After amplification of the targets, PCR 
clean-up was carried out using MEGAquick-spin DNA 
fragment Kit purification (iNtRON, Republic of Korea) 
following manufacturer’s instruction. Purified PCR 
products were sequenced directly by using each primer 
for target gene amplification. The deduced amino acid 
sequences were aligned and analysed with the Laser-
gene® software (DNASTAR, Madison, WI, USA) using 
the reference sequences of 3D7 retrieved from Plasmo-
dium data base [18]. The sequence data from this study 
have been submitted to GenBank under accession num-
bers KJ956790–KJ956797 and KY195978–195988.
Real‑time PCR for copy number analysis of the pfmdr1 
gene
Copy number analysis on pfmdr1 genes was carried out 
according to procedures described previously [19, 20]. 
Briefly, each 20  μL contained 10  μL of multiplex PCR 
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ROX master mix, 0.3  µM of primers, 0.2  µM of probe, 
0.3 µM of forward and reverse β-tubulin gene and 2 µL 
of template DNA. In each run of real-time PCR, 3D7 and 
Dd2 strain were used as known control for copy number 
analysis. The thermal cycling conditions were 95  °C for 
5 min and then 40 cycles of 95 °C for 15 s and 58 °C for 
1 min by ABI 7500 (Applied Biosystems, Foster City, CA, 
USA).
Statistical analysis
All data were double checked and analysed by Microsoft 
Excel and SPSS (Version 22.0. Armonk, NY: IBM Corp). 
Prevalence of each molecular markers was separately and 
combined analysed as percentage. Age group, sex and 
parasitaemia were analysed for association on prevalence 
of each molecular markers by Chi square test with 95% 
confidence interval. Multiple and single copy number of 
pfmdr1 genes and k13 mutations were analysed with co-
occurrence of other molecular markers.
Ethical approval and consent to participate
The study was conducted after receiving ethical approval 
from the institutional ethical committee, Depart-
ment of Medical Research, Myanmar (Approval no. 52/
ethic/2012). Written consent was taken from all partici-
pants. Participation in this study was entirely voluntary.
Results
A total of 100 P. falciparum positive samples were 
included in this study, and as collection was migrant 
populations in gold mining areas, most were from men 
of working age. The median parasite density was 11,166 
Fig. 1 Map of the Bago Region showing the numbers of cases of falciparum malaria diagnosed within each administrative township who reported 
that they were migrant goldmine workers. The study site, Shwegyin showed the highest reported number of cases of malaria from migrant gold‑
mine workers than from neighbouring areas as of 2010. It is one of the Tier I areas of Myanmar’s artemisinin resistance containment zone
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parasites/µL (range 270–110,472 parasites/µL). The 
basic demographic characteristics of the participants are 
shown in Table 1.
All of the samples were well amplified for all the 
molecular markers. Kelch gene, k13 (PF3D7_1343700) 
sequences analysis revealed that 21/100 (21%) sam-
ples were non-synonymous mutation after amino acid 
440. There were only four mutation sites were observed. 
Among them, C580Y accounted for (9/21, 42.9%), P667T 
(5/21, 23.8%), P574L (5/21, 23.8%) and M476I (2/21, 
9.5%).
Similarly, V127M mutation of pfarps10 (PF3D7_ 
1460900.1) accounted for 41/100 (41.0%), D153Y muta-
tion of pffd (PF3D7_1318100) for (64/100, 64.0%), T484I 
of pfmdr2 (PF3D7_1447900) for (58/100, 58.0%), F1390I of 
pfmrp1 (PF3D7_0112200) for (24/100, 24.0%), S1188L of 
pfcnbp (PF3D7_1417400) for (17/100, 17.0%), S1158A of 
pfrad5 (PF3D7_1343400) for (46/100, 46.0%), and N1131I of 
pfrad5 for (7/100, 7.0%) (Table 2).
Pfmdr1 copy number analysis showed that 89/100, 89% 
were single copy number and overall mean copy num-
ber of 1.296. Among the multiple copy number samples, 
eight samples were two copies, two samples were three 
copies and one sample was six copy number. There was 
no correlation on mutations of the molecular mark-
ers or multiple copy numbers of the pfmdr1 gene with 
the age group (p = 0.5310), sex (p = 0.2911) and hyper-
parasitaemia (p  =  0.2311). Based on the co-occurrence 
of the different mutations among seven markers and 
pfmdr1 copy number, 54 isotypes were observed (Addi-
tional file  2). Only three samples showed no mutation 
with single copy number of pfmdr1. An additional 11 
samples were observed that had only one mutation of 
molecular markers. Among the multiple copy number of 
pfmdr1 samples, T484I of pfmdr2 mutation showed 9/11 
(81.8%), D153Y of pffd found as 6/11 (54.4%) and pfrad5 
accounted for 5/11 (45.5%). A significantly higher mutant 
rate of pfmdr2 was observed among the pfmdr1 multiple 
copy number (p = 0.0307) (Fig. 3).
As k13 gene mutation is a well-known marker for 
artemisinin resistance, co-occurrence of k13 mutants 
and other marker mutants were also assessed. Among 
the 21 samples of k13 mutants, D153Y of pffd (9/21, 
42.9%), V127M of pfarps (8/21, 38.1%), T484I of pfmdr2 

















No. of examination Positive cases
Fig. 2 Occupation of the examined cases and malaria cases in active cases detection. Data were retrieved from the township active case detection 
[14] report conducted in 2010. Goldmine workers were the majority of malaria cases in this study site. Taung‑yar: slash‑and‑burn cultivation
Table 1 Basic demographic characteristics of  the partici-
pants
Total participants (n) 100
Male: female 9:1
Median age (range) 23
Working age group (18–50 years) 78
Median parasite density (range) (parasites/µL) 11,166 (270–110,472)
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pfrad5 (5/21, 23.8%) and S1188L of pfcnbp (2/21, 9.5%) 
were observed. The pfmdr2 and pfrad5 mutations were 
at a higher mutant rate among k13 wild-type samples 
(p = 0.0004 and p = 0.0217, respectively (Fig. 4).
Discussion
In this study, a total of 100 uncomplicated falciparum 
malaria patients from migrant goldminers were included 
for molecular analysis. Well-known artemisinin resist-
ance molecular marker, k13 genes as well as other mark-
ers, including pfarps10, pffd, pfmdr2, pfmrp1, pfcnbp, and 
pfrad5 genes were analysed. Moreover, to estimate meflo-
quine or lumefantrine resistance, pfmdr1 copy numbers 
were assessed.
Currently, k13 is the only molecular markers confirmed 
by transfection and clinical data [11, 21]. Although more 
than one hundred of k13 mutations were reported, 
non-synonymous mutations after amino acid position 
440 were found to be linked with artemisinin resist-
ance [21, 22]. In this study, approximately one-fifth of 
the samples (21%) showed four non-synonymous muta-
tions in k13 genes. Among them, C580Y is predominant 
(9/21, 42.86%) followed by P574L (5/21, 23.81%), P667T 
(5/21, 23.81%) and M476I (2/21, 9.523%). The C580Y, a 
validated marker for artemisinin resistance has been 
observed in falciparum endemic countries in South–east 
Asia region [22, 23]. In Myanmar, C580Y mutation was 
observed in 11% of the samples in Kawthaung, southern 
Myanmar. Although it was also reported in Kayin State, 
Myanmar–Thai border area [24], previous survey in Shw-
egyin showed no C580Y mutation [25]. Meanwhile, it 
has been increasing in Thai side of the border area [23]. 
In this study, C580Y was detected as 9/21 (42.9%) of all 
non-synonymous mutations in K13 propeller region and 
might be increasing in prevalence, although the overall 
proportion of isolates with mutations in the propeller 
region does not appear to have changed compared to the 
previous study conducted in the same study site [26].
Although P667T and M476I were not common k13 
mutations, they were also reported as associated markers 
with delayed parasite clearance after treatment with ACT 
in Thailand [27] and Cambodia [11]. Interestingly, in 
this study, P667T was the first reported k13 mutation in 
Myanmar, although it was observed as one of the markers 
showing delayed parasite clearance in Thailand [23].
According to the genome-wide association study 
(GWAS) [14], other markers, such as pfarps10, pffd, 
pfmdr2, and pfcrt also indicate a genetic background 
predisposing to become k13 mutant. Moreover, these 
markers showed equal geographical distribution of k13 
mutations [14]. In this study, D153Y of pffd showed the 
highest mutant rate that accounted for 64%, followed by 
T484I of pfmdr2 (58%) and V127M of pfarps10 (41%), 
reflecting similar findings by GWAS at the same study 
site. Moreover, these markers were also reported in 
asymptomatic infections among the local residents of this 
study site [28]. However, there is no enough evidence on 
the interpretation and mechanism of these markers.
Before discovery of K13 molecular marker, pfmrp1, pfc-
nbp and pfrad5 were identified as potential markers asso-
ciated with artemisinin resistance. Among them, pfmrp1 
and pfcnbp are denoted as the markers of less certain 
evidence. The F1980I mutation of pfmrp1 was found as 
an artemether–lumefantrine combination, reflecting 
multi-drug resistance status, especially for lumefantrine 
[29, 30]. However, no mutations in pfmrp1 that showed 
the delayed clearance of parasite was identified in GWAS. 
It may be because of the phenotype used in GWAS and 
the markers are unlikely to be of relevance to artemisinin 
resistance in Southeast Asia region [14]. Meanwhile, 
Table 2 Summary of the single nucleotide polymorphisms (SNPs) of the molecular markers
All of the non-synonymous mutations are listed and the changes of nucleotide from reference sequences (3D7) are shown in bold
Target genes SNPs Codon position Amino acid (nucleotide) sequence No. of isolates/
total no. of cases
Reference Mutant
k13 C580Y 580 C (TGT) Y (TAT) 9/100
P574L 574 P (CCT) L (CTT) 5/100
P667T 667 P (CCA) T (ACA) 5/100
M476I 476 M (ATG) I (ATA) 2/100
pfarps10 V127M 127 V (GTG) M (ATG) 41/100
pffd D153Y 153 D (GAC) Y (TAC) 64/100
pfmdr2 T484I 484 T (ACA) I (ATA) 58/100
pfmrp1 F1390I 1390 F (TTT) I (ATT) 24/100
pfcnbp S1188L 1188 S (TCG) L (TTG) 17/100
pfrad5 N1131I 1131 N (AAT) I (ATT) 7/100
S1158A 1158 S (TCA) A (GCA) 46/100
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pfcnbp and pfrad5 were reported as potential candi-
dates to assess delayed parasite clearance of parasites as 
these two proteins are involved in post-replication repair 
process [13]. However, pfcnbp is a gene annotated as a 
pseudogene [13] and it did not appear as an important 
markers related with delayed parasite clearance in GWAS 
in South–east Asia region [14].
The marker that are likely to have been associated with 
artemisinin resistance only because of the linkage dis-
equilibrium include pfrad5. It is important to understand 
that mutations in pfrad5 was almost certainly associated 
with artemisinin resistance [13] because of the linkage 
to the C580Y of Cambodia isolates in k13 genes that was 
close to pfrad5 on chromosome 13. In this study, 46.0, 
24.0 and 17.0% were noted as non-synonymous muta-
tions in pfrad5, pfmrp1 and pfcnbp. However, the k13 
mutation in Myanmar has a different genetic background 
to that in Cambodia and it is unable to interpret directly 
based on these mutations in pfrad5, pfmrp1 and pfcnbp 
in Myanmar.
The pfmdr1 multiple copy number also linked to 
resistance to ACT, especially for combinational therapy 
with mefloquine [31]. Both k13 mutations and pfmdr1 
multiple copy in clinical samples increased risk of 
treatment failure by up to 14 times [23]. In this study, 
pfmdr1 multiple copy was observed in 11% of the sam-
ples, which was higher than a previous multi-site study 
in Myanmar [20], but similar to a multi-countries study 
conducted in Southeast Asia region [32] and lower 
than a study conducted in Thailand [23]. Among the 
pfmdr1 multiple copy number samples, eight were two 
copies, two were three copies and one sample showed 
six copies. Only one sample showed both k13 and 






















































K13 pfarps10 pffd pfmdr2 pfmrp1 pfcnbp pfrad5
a
b
Fig. 3 Co‑occurrence of molecular markers among pfmdr1 multiple and single copy number. The distribution of single and multiple copy number 
of pfmdr1 gene (a) and co‑occurrence of other molecular markers among single and multiple copy number of pfmdr1 gene (b)
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(T484I) showed the significantly higher mutant rate in 
pfmdr1 copy number, reflecting potential partner drug 
resistance.
Conclusions
In this study, artemisinin resistance molecular mark-
ers among falciparum-infected samples from migrant 
goldminers were first reported. There are very few stud-
ies focusing on drug resistance in migrant populations 
although they have been recognized as a target popula-
tion in containment programmes. High mutant rate of 
artemisinin resistance molecular marker, k13 in migrant 
goldmine workers alert to emphasize the surveillance on 
artemisinin resistance in this target group population. 
Although high co-occurrence of k13 and pfmdr1 copy 
number was not observed, a significant 11% of samples 
with multiple copy number of pfmdr1 showed potential 
partner drug resistance. Scaling-up of clinical and molec-
ular surveillance of migrant and mobile populations 
should be emphasized in the strategy to eliminate arte-
misinin resistance in the Greater Mekong Sub-region.
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